Abstract
Erythropoietin (Epo) has a long-lasting history as the hormon that allows production of red blood cells. It is now well established that, besides erythropoiesis, Epo has the ability to sustain proliferation of myeloid lineages. More recently, extra-haematological roles have been described for Epo. Its receptor, EpoR, has been detected at the membrane of several neoplastic and normal cell types from the central nervous system and other non haematological cell lines. Whereas Epo-EpoR have been detected several years ago in some extra-haematological normal lineages, their role has long been underestimated whereas they may be crucial for proliferation and survival. Consequently, efforts have recently increased to identify the precise role of Epo-EpoR in a variety of cell types. This allowed identification of physiologically relevant targets that led to original therapeutic strategies.
Keywords: Erythropoietin, neuroprotection, apoptosis, central nervous system, endothelium
Cardiovascular & Hematological Disorders-Drug Targets
Title: Extra-Hematopoietic Effects of Erythropoietin
Volume: 8 Issue: 3
Author(s): Alain Cariou, Stephanie Andre and Yann-Erick Claessens
Affiliation:
Keywords: Erythropoietin, neuroprotection, apoptosis, central nervous system, endothelium
Abstract: Erythropoietin (Epo) has a long-lasting history as the hormon that allows production of red blood cells. It is now well established that, besides erythropoiesis, Epo has the ability to sustain proliferation of myeloid lineages. More recently, extra-haematological roles have been described for Epo. Its receptor, EpoR, has been detected at the membrane of several neoplastic and normal cell types from the central nervous system and other non haematological cell lines. Whereas Epo-EpoR have been detected several years ago in some extra-haematological normal lineages, their role has long been underestimated whereas they may be crucial for proliferation and survival. Consequently, efforts have recently increased to identify the precise role of Epo-EpoR in a variety of cell types. This allowed identification of physiologically relevant targets that led to original therapeutic strategies.
Export Options
About this article
Cite this article as:
Cariou Alain, Andre Stephanie and Claessens Yann-Erick, Extra-Hematopoietic Effects of Erythropoietin, Cardiovascular & Hematological Disorders-Drug Targets 2008; 8 (3) . https://dx.doi.org/10.2174/187152908785849143
DOI https://dx.doi.org/10.2174/187152908785849143 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Relaxin Receptors - New Drug Targets for Multiple Disease States
Current Drug Targets Antiplatelet Therapy in TAVI: Current Clinical Practice and Recommendations
Current Pharmaceutical Design Pharmacogenomics in Drug Induced Liver Injury
Current Drug Metabolism ABC Transporters and Sterol Absorption
Current Drug Targets - Cardiovascular & Hematological Disorders Adipokines, Metabolism and the Immune Response in the Regulation of Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents P2X Receptors in the Cardiovascular System and their Potential as Therapeutic Targets in Disease
Current Medicinal Chemistry Vascular Disease and Insulin-Like Growth Factor-1
Vascular Disease Prevention (Discontinued) Vascular Endothelin and Hypertension - From Receptors to Medicine
Current Hypertension Reviews Novel Targets for Cardiac Antiarrhythmic Drug Development
Current Pharmaceutical Design Intravenous Antihypertensives within Cardiovascular-Based Continuity of Care
Current Vascular Pharmacology Pharmacokinetics-Pharmacology Disconnection of Herbal Medicines and its Potential Solutions with Cellular Pharmacokinetic-Pharmacodynamic Strategy
Current Drug Metabolism Metabolic Syndrome - Risk Factors for Atherosclerosis and Diabetes
Current Diabetes Reviews Does in vitro Fertilisation Increase Type 2 Diabetes and Cardiovascular Risk?
Current Diabetes Reviews Cellular Signaling Crosstalk Between Multiple Receptors for Investigation of Pathophysiology in Multifactorial Diseases - What is Clinically-Relevant Crosstalk?
Current Medicinal Chemistry Hemicellulose from Plant Biomass in Medical and Pharmaceutical Application: A Critical Review
Current Medicinal Chemistry The Applications of Pharmacogenomics to Neurological Disorders
Current Molecular Medicine Annexin A5 Imaging: An Academic Research – Clinical Trials and Theses
Current Molecular Imaging (Discontinued) Visfatin/PBEF and Atherosclerosis-Related Diseases
Current Vascular Pharmacology Type 2 Diabetes Mellitus and the Elderly: An Update on Drugs Used to Treat Glycaemia
Current Vascular Pharmacology Secondary Stroke Prevention in Patients with Cryptogenic Stroke and Patent Foramen Ovale
Vascular Disease Prevention (Discontinued)